<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECTIVE: To evaluate efficacy and safety of switching from twice-daily exenatide to once-daily liraglutide or of 40 weeks of continuous liraglutide therapy </plain></SENT>
<SENT sid="1" pm="."><plain>RESEARCH DESIGN AND METHODS: When added to oral antidiabetes drugs in a 26-week randomized trial (Liraglutide Effect and Action in <z:mp ids='MP_0002055'>Diabetes</z:mp> [LEAD]-6), liraglutide more effectively improved A1C, fasting plasma <z:chebi fb="105" ids="17234">glucose</z:chebi>, and the homeostasis model of beta-cell function (HOMA-B) than exenatide, with less persistent <z:hpo ids='HP_0002018'>nausea</z:hpo> and <z:hpo ids='HP_0001943'>hypoglycemia</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>In this 14-week extension of LEAD-6, patients switched from 10 microg twice-daily exenatide to 1.8 mg once-daily liraglutide or continued liraglutide </plain></SENT>
<SENT sid="3" pm="."><plain>RESULTS: Switching from exenatide to liraglutide further and significantly reduced A1C (0.32%), fasting plasma <z:chebi fb="105" ids="17234">glucose</z:chebi> (0.9 mmol/l), body weight (0.9 kg), and systolic blood pressure (3.8 mmHg) with minimal minor <z:hpo ids='HP_0001943'>hypoglycemia</z:hpo> (1.30 episodes/patient-year) or <z:hpo ids='HP_0002018'>nausea</z:hpo> (3.2%) </plain></SENT>
<SENT sid="4" pm="."><plain>Among patients continuing liraglutide, further significant decreases in body weight (0.4 kg) and systolic blood pressure (2.2 mmHg) occurred with 0.74 episodes/patient-year of minor <z:hpo ids='HP_0001943'>hypoglycemia</z:hpo> and 1.5% experiencing <z:hpo ids='HP_0002018'>nausea</z:hpo> </plain></SENT>
<SENT sid="5" pm="."><plain>CONCLUSIONS: Conversion from exenatide to liraglutide is well tolerated and provides additional glycemic control and cardiometabolic benefits </plain></SENT>
</text></document>